Efficacy of ART during pregnancy

ARVs used during pregnancy should be selected only if potential benefit justifies the potential risk5

1. Hardy H, et al. 1st International Workshop on HIV and Women, 2011. Poster 016
2. van der Lugt J, et al. Antivir Ther.2009;14:443–50
3. Tubiana, R. Et al. 18th Conference on retroviruses and Opportunistic Infections 2011 Paper 125LB
4. Jaworsky D, et al. Antivir Ther 2010;15:677–80
5. SmPCs. Available at http://www.ema.europa.eu Accessed March 2011



Mma Bana Study: Study design1

560 women with CD4 ≥200 cells/mm3 randomised to:

module3.2-section3-5

170 women with CD4 <200 cells/mm3 or AIDS enrolled observationally:

module3.2-section3-6

Infants received single-dose NVP at birth and AZT x 1 month

ARVs used during pregnancy should be selected only if potential benefit justifies the potential risk2
1. Shapiro R, et al. N Engl J Med 2010;362:2282–94; 2. SmPCs. Available at http://www.ema.europa.eu Accessed March 2011



Mma Bana: VL to <400 copies/mL did not differ significantly among groups1

module3.2-section3-7

ARVs used during pregnancy should be selected only if potential benefit justifies the potential risk2
1. Shapiro R, et al. N Engl J Med 2010;362:2282–94; 2. SmPCs. Available at http://www.ema.europa.eu Accessed March 2011

module3.2-section3-8